Katayama S, Inaba M, Maruno Y, Morita T, Awata T, Oka Y
Fourth Department of Medicine, Saitama Medical School, Japan.
Hypertens Res. 1997 Dec;20(4):279-86. doi: 10.1291/hypres.20.279.
To clarify the relationship between blood pressure and insulin resistance, we studied the role of glucose transporter 4 (GLUT4) in skeletal muscle and the effect of angiotensin-converting enzyme inhibitor on insulin resistance. Blood pressure and plasma glucose and plasma insulin responses to glucose loading (2 g/kg, i.p.) were measured in spontaneously hypertensive rats (SHRs), Wistar-Kyoto rats (WKYs), and Wistar rats at 8, 12, and 20 wk of age. GLUT4 gene expression and plasma membrane protein content were also determined in the gastrocnemius muscle. SHRs and WKYs at the age of 8 wk had significantly higher plasma glucose levels than did age-matched control Wistar rats. Insulin response also tended to be higher. Glucose intolerance was also present in 12-wk-old SHRs, but normalized at the age of 20 wk. In contrast, WKYs were glucose intolerant at 12 and 20 wk. Gene expression and plasma membrane content of GLUT4 were augmented in both 8-wk-old SHRs and WKYs, indicating a compensatory increase in these variables. Effects of captopril (20-30 mg/kg/d from 8 to 20 wk) on GLUT4 were also investigated in these three strains. Captopril improved steady state plasma glucose levels in association with 1.2- to 2.5-fold higher GLUT4 gene expression and a 1.4-fold increase in skeletal muscle GLUT4 protein in SHRs and WKYs. Our results suggest that (1) not only SHRs but also WKYs may have glucose intolerance and hence insulin resistance; (2) gene expression and protein synthesis of skeletal muscle GLUT4 are probably increased compensatorily, indicating that abnormalities in GLUT4 do not have a pivotal role in the development of insulin resistance in SHRs and WKYs; and (3) captopril stimulates skeletal muscle gene expression and synthesis of GLUT4, providing further evidence of its beneficial effect on glucose metabolism.
为了阐明血压与胰岛素抵抗之间的关系,我们研究了葡萄糖转运蛋白4(GLUT4)在骨骼肌中的作用以及血管紧张素转换酶抑制剂对胰岛素抵抗的影响。在8周、12周和20周龄的自发性高血压大鼠(SHRs)、Wistar-Kyoto大鼠(WKYs)和Wistar大鼠中,测量了血压、血浆葡萄糖以及对葡萄糖负荷(2 g/kg,腹腔注射)的血浆胰岛素反应。还测定了腓肠肌中GLUT4基因表达和质膜蛋白含量。8周龄的SHRs和WKYs的血浆葡萄糖水平显著高于年龄匹配的对照Wistar大鼠。胰岛素反应也有升高趋势。12周龄的SHRs也存在葡萄糖不耐受,但在20周龄时恢复正常。相比之下,WKYs在12周和20周时存在葡萄糖不耐受。8周龄的SHRs和WKYs中GLUT4的基因表达和质膜含量均增加,表明这些变量有代偿性增加。还在这三种品系中研究了卡托普利(8至20周,20 - 30 mg/kg/d)对GLUT4的影响。卡托普利改善了稳态血浆葡萄糖水平,同时SHRs和WKYs中GLUT4基因表达提高了1.2至2.5倍,骨骼肌GLUT4蛋白增加了1.4倍。我们的结果表明:(1)不仅SHRs,而且WKYs可能都存在葡萄糖不耐受,因此存在胰岛素抵抗;(2)骨骼肌GLUT4的基因表达和蛋白质合成可能会代偿性增加,这表明GLUT4异常在SHRs和WKYs胰岛素抵抗的发生发展中不起关键作用;(3)卡托普利刺激骨骼肌GLUT4的基因表达和合成,进一步证明了其对葡萄糖代谢的有益作用。